>> Two other red flags I will look for in the future after my unpleasant Pharmos experience: 1) Murky modes of action. I was always a bit nervous about the 'multiple modes of action' of dexanabinol. It was supposed to be a cannabinoid, but it wasn't active at either of the two known cannabinoid receptors. It sounded like Pharmos wasn't exactly sure how it worked - turned out that it didnt' work. 2) Small biotechs with no big Pharma partners. Pharmos had no partnerships at all. You would think in a hot field like cannabinoids they could have done some sort of collaboration. Now I want to see a small company's science validated by a partnership with a big pharma. I figure these big pharma guys ought to be able to evaluate the potential of some bio-technology much better than I can. <<
Each of these red flags applies in spades to GENR’s Evizon program.
Market Data 
Markets 
AI
